Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising oxaliplatin and capecitabine (XELOX), irinotecan hydrochloride, leucovorin calcium and fluorouracil irinotecan (FOLFIRI)/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acu...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2018/08/15, Vol.57(16), pp.2403-2407 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2407 |
|---|---|
| container_issue | 16 |
| container_start_page | 2403 |
| container_title | Internal Medicine |
| container_volume | 57 |
| creator | Katada, Eiichi Mitsui, Akira Sasaki, Shigeru Uematsu, Norihiko Anan, Chise |
| description | A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising oxaliplatin and capecitabine (XELOX), irinotecan hydrochloride, leucovorin calcium and fluorouracil irinotecan (FOLFIRI)/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acute onset of a headache, drowsiness and seizure with a fever and hypertension. Brain magnetic resonance imaging (MRI) indicated bilateral regions of signal hyperintensity in the white matter with spasms of bilateral cerebral arteries apparent on magnetic resonance angiography. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, and treatments resulted in improvement of the MRI findings, but the patient experienced cerebral infarction and ultimately died of deterioration of cancer on day 26 after the onset of PRES. |
| doi_str_mv | 10.2169/internalmedicine.0284-17 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6148172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2246942563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c667t-b3fe1dd027ce63ec7ec65db01e74cc614c59c58ee1cdc7b84e190f4aa05b4bc93</originalsourceid><addsrcrecordid>eNplkc2O0zAUhS0EYjqFV0CW2LDJYDvO3wYJohkGadAg_rbWjXPTuErsYruVyiPw1LhqqWDY2JL9-ZzrcwihnF0JXjavjY3oLUwz9kYbi1dM1DLj1SOy4LlsskrkxWOyYA2vM5GWC3IZwpqxvK4a8ZRciKYQZSPlgvz65ELSMs7Tz7hDH0w3Ib22GjcjTG4DcdzTL3vbezcjhSGxFOh38AbjnrqBtm7u0gQ9bUecXRzRw8ZgSOc2grHGrug73IE2P7czdHRIRh8xQogQjU7U5CxtIfn5Z-TJAFPA56d9Sb7dXH9tb7O7-_cf2rd3mS7LKmZdPiDveyYqjWWOukJdFn3HOFZS65JLXTS6qBG57nXV1RJ5wwYJwIpOdrrJl-TNUXez7VKAGm30MKmNNzP4vXJg1L831oxq5XYqadc8Rbskr04C3v3YYohqNkHjNIFFtw1KMJ5zJkVRJfTlA3TttofmEiVkqkAUZZ6o-khp70LwOJyH4UwdClcPC1eHwhU_GLz4-zPnh38aTsD9EVinyFd4BsCn_Cf8X7moFC8P68niTOoRvEKb_wa2NM69</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2246942563</pqid></control><display><type>article</type><title>Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Katada, Eiichi ; Mitsui, Akira ; Sasaki, Shigeru ; Uematsu, Norihiko ; Anan, Chise</creator><creatorcontrib>Katada, Eiichi ; Mitsui, Akira ; Sasaki, Shigeru ; Uematsu, Norihiko ; Anan, Chise</creatorcontrib><description>A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising oxaliplatin and capecitabine (XELOX), irinotecan hydrochloride, leucovorin calcium and fluorouracil irinotecan (FOLFIRI)/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acute onset of a headache, drowsiness and seizure with a fever and hypertension. Brain magnetic resonance imaging (MRI) indicated bilateral regions of signal hyperintensity in the white matter with spasms of bilateral cerebral arteries apparent on magnetic resonance angiography. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, and treatments resulted in improvement of the MRI findings, but the patient experienced cerebral infarction and ultimately died of deterioration of cancer on day 26 after the onset of PRES.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.0284-17</identifier><identifier>PMID: 29526944</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>5-Fluorouracil ; Adult ; Angiography ; Antineoplastic Agents, Immunological - therapeutic use ; Bevacizumab ; Bevacizumab - adverse effects ; Bevacizumab - therapeutic use ; Calcium ; Camptothecin - adverse effects ; Camptothecin - analogs & derivatives ; Camptothecin - therapeutic use ; Capecitabine - adverse effects ; Capecitabine - therapeutic use ; Case Report ; Cerebral infarction ; Chemotherapy ; Colon cancer ; Colonic Neoplasms - drug therapy ; Colorectal cancer ; Drowsiness ; Encephalopathy ; Female ; Fever ; FOLFIRI ; Headache ; Humans ; Internal medicine ; Irinotecan ; Leucovorin - adverse effects ; Leucovorin - therapeutic use ; Magnetic resonance imaging ; Metastases ; Metastasis ; mFOLFOX 6 ; Monoclonal antibodies ; Neoplasm Metastasis - drug therapy ; Neuroimaging ; NMR ; Nuclear magnetic resonance ; Organoplatinum Compounds - adverse effects ; Organoplatinum Compounds - therapeutic use ; Oxaliplatin ; Posterior Leukoencephalopathy Syndrome - drug therapy ; Posterior Leukoencephalopathy Syndrome - etiology ; posterior reversible encephalopathy syndrome ; Resonance ; Spasms ; Substantia alba ; Targeted cancer therapy ; Treatment Outcome ; XELOX</subject><ispartof>Internal Medicine, 2018/08/15, Vol.57(16), pp.2403-2407</ispartof><rights>2018 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2018</rights><rights>Copyright © 2018 by The Japanese Society of Internal Medicine 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c667t-b3fe1dd027ce63ec7ec65db01e74cc614c59c58ee1cdc7b84e190f4aa05b4bc93</citedby><cites>FETCH-LOGICAL-c667t-b3fe1dd027ce63ec7ec65db01e74cc614c59c58ee1cdc7b84e190f4aa05b4bc93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148172/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148172/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29526944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katada, Eiichi</creatorcontrib><creatorcontrib>Mitsui, Akira</creatorcontrib><creatorcontrib>Sasaki, Shigeru</creatorcontrib><creatorcontrib>Uematsu, Norihiko</creatorcontrib><creatorcontrib>Anan, Chise</creatorcontrib><title>Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising oxaliplatin and capecitabine (XELOX), irinotecan hydrochloride, leucovorin calcium and fluorouracil irinotecan (FOLFIRI)/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acute onset of a headache, drowsiness and seizure with a fever and hypertension. Brain magnetic resonance imaging (MRI) indicated bilateral regions of signal hyperintensity in the white matter with spasms of bilateral cerebral arteries apparent on magnetic resonance angiography. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, and treatments resulted in improvement of the MRI findings, but the patient experienced cerebral infarction and ultimately died of deterioration of cancer on day 26 after the onset of PRES.</description><subject>5-Fluorouracil</subject><subject>Adult</subject><subject>Angiography</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Bevacizumab</subject><subject>Bevacizumab - adverse effects</subject><subject>Bevacizumab - therapeutic use</subject><subject>Calcium</subject><subject>Camptothecin - adverse effects</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - therapeutic use</subject><subject>Capecitabine - adverse effects</subject><subject>Capecitabine - therapeutic use</subject><subject>Case Report</subject><subject>Cerebral infarction</subject><subject>Chemotherapy</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colorectal cancer</subject><subject>Drowsiness</subject><subject>Encephalopathy</subject><subject>Female</subject><subject>Fever</subject><subject>FOLFIRI</subject><subject>Headache</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Irinotecan</subject><subject>Leucovorin - adverse effects</subject><subject>Leucovorin - therapeutic use</subject><subject>Magnetic resonance imaging</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>mFOLFOX 6</subject><subject>Monoclonal antibodies</subject><subject>Neoplasm Metastasis - drug therapy</subject><subject>Neuroimaging</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Oxaliplatin</subject><subject>Posterior Leukoencephalopathy Syndrome - drug therapy</subject><subject>Posterior Leukoencephalopathy Syndrome - etiology</subject><subject>posterior reversible encephalopathy syndrome</subject><subject>Resonance</subject><subject>Spasms</subject><subject>Substantia alba</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><subject>XELOX</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkc2O0zAUhS0EYjqFV0CW2LDJYDvO3wYJohkGadAg_rbWjXPTuErsYruVyiPw1LhqqWDY2JL9-ZzrcwihnF0JXjavjY3oLUwz9kYbi1dM1DLj1SOy4LlsskrkxWOyYA2vM5GWC3IZwpqxvK4a8ZRciKYQZSPlgvz65ELSMs7Tz7hDH0w3Ib22GjcjTG4DcdzTL3vbezcjhSGxFOh38AbjnrqBtm7u0gQ9bUecXRzRw8ZgSOc2grHGrug73IE2P7czdHRIRh8xQogQjU7U5CxtIfn5Z-TJAFPA56d9Sb7dXH9tb7O7-_cf2rd3mS7LKmZdPiDveyYqjWWOukJdFn3HOFZS65JLXTS6qBG57nXV1RJ5wwYJwIpOdrrJl-TNUXez7VKAGm30MKmNNzP4vXJg1L831oxq5XYqadc8Rbskr04C3v3YYohqNkHjNIFFtw1KMJ5zJkVRJfTlA3TttofmEiVkqkAUZZ6o-khp70LwOJyH4UwdClcPC1eHwhU_GLz4-zPnh38aTsD9EVinyFd4BsCn_Cf8X7moFC8P68niTOoRvEKb_wa2NM69</recordid><startdate>20180815</startdate><enddate>20180815</enddate><creator>Katada, Eiichi</creator><creator>Mitsui, Akira</creator><creator>Sasaki, Shigeru</creator><creator>Uematsu, Norihiko</creator><creator>Anan, Chise</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180815</creationdate><title>Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer</title><author>Katada, Eiichi ; Mitsui, Akira ; Sasaki, Shigeru ; Uematsu, Norihiko ; Anan, Chise</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c667t-b3fe1dd027ce63ec7ec65db01e74cc614c59c58ee1cdc7b84e190f4aa05b4bc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>5-Fluorouracil</topic><topic>Adult</topic><topic>Angiography</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Bevacizumab</topic><topic>Bevacizumab - adverse effects</topic><topic>Bevacizumab - therapeutic use</topic><topic>Calcium</topic><topic>Camptothecin - adverse effects</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - therapeutic use</topic><topic>Capecitabine - adverse effects</topic><topic>Capecitabine - therapeutic use</topic><topic>Case Report</topic><topic>Cerebral infarction</topic><topic>Chemotherapy</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colorectal cancer</topic><topic>Drowsiness</topic><topic>Encephalopathy</topic><topic>Female</topic><topic>Fever</topic><topic>FOLFIRI</topic><topic>Headache</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Irinotecan</topic><topic>Leucovorin - adverse effects</topic><topic>Leucovorin - therapeutic use</topic><topic>Magnetic resonance imaging</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>mFOLFOX 6</topic><topic>Monoclonal antibodies</topic><topic>Neoplasm Metastasis - drug therapy</topic><topic>Neuroimaging</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Oxaliplatin</topic><topic>Posterior Leukoencephalopathy Syndrome - drug therapy</topic><topic>Posterior Leukoencephalopathy Syndrome - etiology</topic><topic>posterior reversible encephalopathy syndrome</topic><topic>Resonance</topic><topic>Spasms</topic><topic>Substantia alba</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><topic>XELOX</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katada, Eiichi</creatorcontrib><creatorcontrib>Mitsui, Akira</creatorcontrib><creatorcontrib>Sasaki, Shigeru</creatorcontrib><creatorcontrib>Uematsu, Norihiko</creatorcontrib><creatorcontrib>Anan, Chise</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katada, Eiichi</au><au>Mitsui, Akira</au><au>Sasaki, Shigeru</au><au>Uematsu, Norihiko</au><au>Anan, Chise</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2018-08-15</date><risdate>2018</risdate><volume>57</volume><issue>16</issue><spage>2403</spage><epage>2407</epage><pages>2403-2407</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>A 44-year-old woman with advanced metastatic colon cancer received chemotherapies comprising oxaliplatin and capecitabine (XELOX), irinotecan hydrochloride, leucovorin calcium and fluorouracil irinotecan (FOLFIRI)/panitumumab and mFOLFOX6/bevacizumab. Fifteen months later, she presented with the acute onset of a headache, drowsiness and seizure with a fever and hypertension. Brain magnetic resonance imaging (MRI) indicated bilateral regions of signal hyperintensity in the white matter with spasms of bilateral cerebral arteries apparent on magnetic resonance angiography. Posterior reversible encephalopathy syndrome (PRES) was diagnosed, and treatments resulted in improvement of the MRI findings, but the patient experienced cerebral infarction and ultimately died of deterioration of cancer on day 26 after the onset of PRES.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>29526944</pmid><doi>10.2169/internalmedicine.0284-17</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2018/08/15, Vol.57(16), pp.2403-2407 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6148172 |
| source | J-STAGE Free; MEDLINE; PubMed Central; PubMed Central Open Access |
| subjects | 5-Fluorouracil Adult Angiography Antineoplastic Agents, Immunological - therapeutic use Bevacizumab Bevacizumab - adverse effects Bevacizumab - therapeutic use Calcium Camptothecin - adverse effects Camptothecin - analogs & derivatives Camptothecin - therapeutic use Capecitabine - adverse effects Capecitabine - therapeutic use Case Report Cerebral infarction Chemotherapy Colon cancer Colonic Neoplasms - drug therapy Colorectal cancer Drowsiness Encephalopathy Female Fever FOLFIRI Headache Humans Internal medicine Irinotecan Leucovorin - adverse effects Leucovorin - therapeutic use Magnetic resonance imaging Metastases Metastasis mFOLFOX 6 Monoclonal antibodies Neoplasm Metastasis - drug therapy Neuroimaging NMR Nuclear magnetic resonance Organoplatinum Compounds - adverse effects Organoplatinum Compounds - therapeutic use Oxaliplatin Posterior Leukoencephalopathy Syndrome - drug therapy Posterior Leukoencephalopathy Syndrome - etiology posterior reversible encephalopathy syndrome Resonance Spasms Substantia alba Targeted cancer therapy Treatment Outcome XELOX |
| title | Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A59%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Posterior%20Reversible%20Encephalopathy%20Syndrome%20after%20a%20Variety%20of%20Combined%20Chemotherapies%20Containing%20Bevacizumab%20for%20Metastatic%20Colon%20Cancer&rft.jtitle=Internal%20Medicine&rft.au=Katada,%20Eiichi&rft.date=2018-08-15&rft.volume=57&rft.issue=16&rft.spage=2403&rft.epage=2407&rft.pages=2403-2407&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.0284-17&rft_dat=%3Cproquest_pubme%3E2246942563%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2246942563&rft_id=info:pmid/29526944&rfr_iscdi=true |